Published in Vasc Health Risk Manag on January 01, 2008
Regulation of vascular tone by adipocytes. BMC Med (2011) 1.01
Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials. Vasc Health Risk Manag (2009) 0.90
Direct renin inhibition exerts an anti-hypertrophic effect associated with improved mitochondrial function in post-infarction heart failure in diabetic rats. Cell Physiol Biochem (2012) 0.89
Restoration of the blood pressure circadian rhythm by direct renin inhibition and blockade of angiotensin II receptors in mRen2.Lewis hypertensive rats. Ther Adv Cardiovasc Dis (2012) 0.85
Direct renin inhibition with aliskiren protects against myocardial ischemia/reperfusion injury by activating nitric oxide synthase signaling in spontaneously hypertensive rats. J Am Heart Assoc (2014) 0.83
Renal functional responses to selective intrarenal renin inhibition in Cyp1a1-Ren2 transgenic rats with ANG II-dependent malignant hypertension. Am J Physiol Renal Physiol (2011) 0.79
Can Aliskiren be Considered as a New Novel Drug for Hypertension? Cureus (2015) 0.78
Algal Proteins: Extraction, Application, and Challenges Concerning Production. Foods (2017) 0.77
Long-term safety and efficacy of telmisartan/amlodipine single pill combination in the treatment of hypertension. Vasc Health Risk Manag (2013) 0.76
Genetic Variants of C-5312T REN Increased Renin Levels and Diastolic Blood Pressure Response to Angiotensin Receptor Blockers. Int J Hypertens (2015) 0.75
Fixed combinations in the pragmatic management of hypertension: focus on aliskiren and hydrochlorothiazide as a single pill. Integr Blood Press Control (2010) 0.75
Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med (2008) 19.76
Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med (2008) 11.61
A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res (2000) 6.78
Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest (2002) 6.27
Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med (1972) 4.80
Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet (2007) 3.98
Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med (1991) 3.86
Renin-angiotensin system and atherothrombotic disease: from genes to treatment. Arch Intern Med (2003) 2.98
Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int (2006) 2.85
Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol (2007) 2.38
Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension (2005) 1.89
Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation (2005) 1.89
Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun (2003) 1.74
Plasma renin activity and ischemic heart disease. N Engl J Med (1993) 1.71
Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension (2002) 1.71
Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N Engl J Med (1985) 1.70
The preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med (1957) 1.68
Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol (2006) 1.67
Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail (2008) 1.65
A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. J Hum Hypertens (2007) 1.59
Prediction of myocardial infarction by N-terminal-pro-B-type natriuretic peptide, C-reactive protein, and renin in subjects with cerebrovascular disease. Circulation (2005) 1.55
Chimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes. J Biol Chem (1993) 1.53
Update on tissue renin-angiotensin systems. J Mol Med (Berl) (2008) 1.50
Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension (2003) 1.46
Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am J Hypertens (1997) 1.41
The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol (1999) 1.38
Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem Biol (2000) 1.37
Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens (2007) 1.36
Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab (1989) 1.35
Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol (2004) 1.34
Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens (2007) 1.33
The multiple actions of angiotensin II in atherosclerosis. Regul Pept (2000) 1.29
Determinants of interindividual variation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humans. J Hypertens (1998) 1.28
Structure of recombinant human renin, a target for cardiovascular-active drugs, at 2.5 A resolution. Science (1989) 1.19
Binding properties of rat prorenin and renin to the recombinant rat renin/prorenin receptor prepared by a baculovirus expression system. Int J Mol Med (2006) 1.17
Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes. Proc Natl Acad Sci U S A (1992) 1.16
Direct Renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension (2007) 1.16
Mannose 6-phosphate receptor-mediated internalization and activation of prorenin by cardiac cells. Hypertension (1997) 1.14
Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens (2005) 1.10
Stereochemical analysis of peptide bond hydrolysis catalyzed by the aspartic proteinase penicillopepsin. Biochemistry (1985) 1.10
Exploring the structure and function of zinc metallopeptidases: old enzymes and new discoveries. Biochem Soc Trans (2003) 0.98
An alternative transcript of the rat renin gene can result in a truncated prorenin that is transported into adrenal mitochondria. Circ Res (1999) 0.96
Renin/prorenin receptors. Kidney Int (2006) 0.96
Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos (2007) 0.95
Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res (2006) 0.95
Plasma renin levels and vascular complications in hypertension. Br Med J (1973) 0.94
Proteolytic processing of human prorenin in renal and non-renal tissues. Kidney Int (1994) 0.91
Inhibitors of renin as potential therapeutic agents. J Enzyme Inhib (1987) 0.87
Diabetes and retinal vascular disorders: role of the renin-angiotensin system. Expert Rev Mol Med (2004) 0.86
Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin Pharmacol Ther (2005) 0.86
Human prorenin: pathophysiology and clinical implications. Clin Exp Hypertens A (1988) 0.85
Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. Br J Clin Pharmacol (2004) 0.85
Source of plasma prorenin in early and late pregnancy: observations in a patient with primary ovarian failure. J Clin Endocrinol Metab (1987) 0.83
The (pro)renin receptor: therapeutic consequences. Expert Opin Investig Drugs (2006) 0.82
Plasma prorenin response to human chorionic gonadotropin in ovarian-hyperstimulated women: correlation with the number of ovarian follicles and steroid hormone concentrations. Proc Natl Acad Sci U S A (1987) 0.82
Highest concentrations of prorenin and human chorionic gonadotropin in gestational sacs during early human pregnancy. J Clin Endocrinol Metab (1992) 0.82
Conformational changes in prorenin during renin inhibition in vitro and in vivo. J Hypertens (2006) 0.80
Prorenin secretion from human testis: no evidence for secretion of active renin or angiotensinogen. J Clin Endocrinol Metab (1988) 0.80
Receptor-mediated actions of renin and prorenin. Kidney Int (2006) 0.79
Prorenin anno 2008. J Mol Med (Berl) (2008) 0.78
Renin inhibition: the holy grail of renin-angiotensin system blockade? J Hum Hypertens (2007) 0.78
Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet (2009) 6.25
Day-night dip and early-morning surge in blood pressure in hypertension: prognostic implications. Hypertension (2012) 5.60
Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension (2004) 4.38
Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients. J Hypertens (2011) 3.50
Ambulatory blood pressure and cardiovascular outcome in relation to perceived sleep deprivation. Hypertension (2007) 2.63
Short- and long-term incidence of stroke in white-coat hypertension. Hypertension (2004) 2.58
Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension (2005) 2.54
Patients with hibernating myocardium show altered left ventricular volumes and shape, which revert after revascularization: evidence that dyssynergy might directly induce cardiac remodeling. J Am Coll Cardiol (2006) 2.02
Impact of blood pressure variability on cardiac and cerebrovascular complications in hypertension. Am J Hypertens (2007) 1.97
Prevalence and correlates of self-reported sexual dysfunction in CKD: a meta-analysis of observational studies. Am J Kidney Dis (2010) 1.81
Sexual dysfunction in women with ESRD requiring hemodialysis. Clin J Am Soc Nephrol (2012) 1.56
Prognostic significance of isolated, non-specific left ventricular repolarization abnormalities in hypertension. J Hypertens (2004) 1.56
Regression of left ventricular hypertrophy and prevention of stroke in hypertensive subjects. Am J Hypertens (2006) 1.51
Do angiotensin II receptor blockers increase the risk of myocardial infarction? Eur Heart J (2005) 1.47
Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis. Eur Heart J (2009) 1.47
Prognostic value of serial electrocardiographic voltage and repolarization changes in essential hypertension: the HEART Survey study. Am J Hypertens (2007) 1.43
Atrial fibrillation in hypertension: predictors and outcome. Hypertension (2003) 1.40
Blood pressure lowering in the oldest old. J Hypertens (2010) 1.40
The voltage of R wave in lead aVL improves risk stratification in hypertensive patients without ECG left ventricular hypertrophy. J Hypertens (2009) 1.38
Multivariable analysis in cerebrovascular research: practical notes for the clinician. Cerebrovasc Dis (2013) 1.38
Plasma cytokine levels in patients with obstructive sleep apnea syndrome: a preliminary study. J Sleep Res (2003) 1.25
Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens (2003) 1.16
Home Blood Pressure Measurements Will Not Replace 24-Hour Ambulatory Blood Pressure Monitoring. Hypertension (2009) 1.16
Masked hypertension: evaluation, prognosis, and treatment. Am J Hypertens (2010) 1.12
Osmophobia as an early marker of migraine: a follow-up study in juvenile patients. Cephalalgia (2012) 1.12
Ambulatory blood pressure for cardiovascular risk stratification. Circulation (2007) 1.10
Executive dysfunction in children affected by obstructive sleep apnea syndrome: an observational study. Neuropsychiatr Dis Treat (2013) 1.09
Clinical usefulness of ambulatory blood pressure monitoring. J Am Soc Nephrol (2004) 1.08
Contribution of the ABP-International study to the definition of night-time tachycardia. J Hypertens (2014) 1.07
Dysphagia following Stroke. Eur Neurol (2004) 1.05
Cardiovascular risk assessment in low-resource settings: a consensus document of the European Society of Hypertension Working Group on Hypertension and Cardiovascular Risk in Low Resource Settings. J Hypertens (2014) 1.04
Maternal stress and childhood migraine: a new perspective on management. Neuropsychiatr Dis Treat (2013) 1.03
Primary nocturnal enuresis as a risk factor for sleep disorders: an observational questionnaire-based multicenter study. Neuropsychiatr Dis Treat (2013) 1.01
Can headache impair intellectual abilities in children? An observational study. Neuropsychiatr Dis Treat (2012) 1.00
Influence of blood pressure reduction on composite cardiovascular endpoints in clinical trials. J Hypertens (2010) 0.98
Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens (2008) 0.97
Visuomotor competencies and primary monosymptomatic nocturnal enuresis in prepubertal aged children. Neuropsychiatr Dis Treat (2013) 0.97
Testis-sparing surgery for the conservative management of small testicular masses: an update. Anticancer Res (2013) 0.97
Risk of cardiovascular disease in relation to achieved office and ambulatory blood pressure control in treated hypertensive subjects. J Am Coll Cardiol (2002) 0.97
Echocardiographic left ventricular hypertrophy in hypertension: marker for future events or mediator of events? Curr Opin Cardiol (2007) 0.96
Prognostic impact from clinic, daytime, and night-time systolic blood pressure in nine cohorts of 13,844 patients with hypertension. J Hypertens (2014) 0.96
Prevalence and severity of oral disease in adults with chronic kidney disease: a systematic review of observational studies. Nephrol Dial Transplant (2013) 0.95
Temperamental characteristics in childhood migraine without aura: a multicenter study. Neuropsychiatr Dis Treat (2013) 0.95
Comparative assessment of angiotensin receptor blockers in different clinical settings. Vasc Health Risk Manag (2009) 0.94
[The Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the weapons are ready]. Rev Esp Cardiol (2003) 0.93
Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials. Vasc Health Risk Manag (2009) 0.90
Change in cardiovascular risk profile by echocardiography in low- or medium-risk hypertension. J Hypertens (2002) 0.90
Improved cardiovascular risk stratification by a simple ECG index in hypertension. Am J Hypertens (2003) 0.90
New-onset diabetes, antihypertensive treatment, and outcome. Hypertension (2007) 0.90
Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. Nephrol Dial Transplant (2011) 0.90
Validation of the A&D UA-774 (UA-767Plus) device for self-measurement of blood pressure. Blood Press Monit (2004) 0.89
Tight blood pressure control in diabetes: evidence-based review of treatment targets in patients with diabetes. Curr Cardiol Rep (2012) 0.88
Aliskiren versus ramipril in hypertension. Ther Adv Cardiovasc Dis (2010) 0.88
Ret/PTC activation does not influence clinical and pathological features of adult papillary thyroid carcinomas. Eur J Endocrinol (2003) 0.87
Atrial fibrillation and mortality in patients with acute myocardial infarction: a systematic overview and meta-analysis. Curr Cardiol Rep (2012) 0.87
White-coat hypertension in adults. Blood Press Monit (2005) 0.86
Predictive value of night-time heart rate for cardiovascular events in hypertension. The ABP-International study. Int J Cardiol (2013) 0.86
Sex-related penile fracture with complete urethral rupture: A case report and review of the literature. Arch Ital Urol Androl (2015) 0.85
Self-concept evaluation and migraine without aura in childhood. Neuropsychiatr Dis Treat (2013) 0.85
Is the definition of daytime and nighttime blood pressure prognostically relevant? Blood Press Monit (2008) 0.85
Telmisartan for the reduction of cardiovascular morbidity and mortality. Expert Rev Clin Pharmacol (2011) 0.85